Glycomimetics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Ryan Lynch, See Remarks of Glycomimetics Inc, sold 240 shares of common stock on September 16, 2026 for $17.90 per share.
Jan Pinkas, Chief Scientific Officer of Glycomimetics Inc, sold 658 shares of common stock on September 16, 2026 for $17.90 per share.
Ellie Eunkyung Im, Chief Medical Officer of Glycomimetics Inc, sold 623 shares of common stock on September 16, 2026 for $17.90 per share.
Form 4: Glycomimetics CFO Sells Shares
Richard William Scalzo, Chief Financial Officer of Glycomimetics Inc, sold 568 shares of common stock on September 16, 2026 for $17.90 per share.
Barbara Harlin Bispham, See Remarks of Glycomimetics Inc, sold 620 shares of common stock on September 16, 2026 for $17.90 per share.
Form 4: Glycomimetics CEO Sells Shares
Joshua T Brumm, Chief Executive Officer and a Director of Glycomimetics Inc, sold 9,447 shares of common stock on September 16, 2026.
Form 4: Glycomimetics COO Sells Shares
Jonathan Mcneill, President and COO of Glycomimetics Inc, sold 4,570 shares of common stock on September 16, 2026.
Fairmount Funds Management LLC and 3 others reported changes in beneficial ownership of Glycomimetics Inc common stock on July 16, 2026.
Crescent Biopharma, Inc. director Jonathan Violin was granted 11,050 stock options as part of his compensation package.
Director David Charles Lubner was granted 11,050 stock options in Crescent Biopharma, Inc. as part of his compensation.
Director Alexandra Balcom was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity incentive.
Director Susan Moran was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity compensation arrangement.
Fairmount Funds Management and associated directors were granted 11,050 stock options in Crescent Biopharma, Inc.
Crescent Biopharma's Chief Scientific Officer, Jan Pinkas, was granted 22,507 Restricted Stock Units and options to purchase 70,025 ordinary shares.
Crescent Biopharma's Chief Business Officer, Christopher Doughty, received significant equity awards including Restricted Stock Units and stock options, aligning his interests with long-term company performance.
Crescent Biopharma's CEO, Joshua T. Brumm, received significant equity awards including Restricted Stock Units and stock options, vesting over several years.
Crescent Biopharma's Chief Financial Officer, Richard William Scalzo, received significant equity awards including Restricted Stock Units and stock options.
Crescent BioPharma's President and COO, Jonathan McNeill, reported the acquisition of 25,507 Restricted Stock Units and options for 78,029 ordinary shares.
Crescent Biopharma's Chief Medical Officer, Ellie Eunkyung Im, received significant equity awards including Restricted Stock Units and stock options.
Crescent Biopharma's Treasurer, SVP of Finance, and Chief Accounting Officer, Ryan Lynch, received significant equity awards including Restricted Stock Units and stock options.
Crescent BioPharma's General Counsel, Barbara Harlin Bispham, received significant equity awards including RSUs and stock options, aligning her interests with long-term company performance.
Crescent BioPharma's President and COO, Jonathan McNeill, was granted 172,836 stock options with an exercise price of $13.17, vesting over 48 months.
Crescent Biopharma's CEO, Joshua T. Brumm, was granted 345,672 stock options with an exercise price of $13.17, vesting over 48 months.
Fairmount Funds Management and related entities increased their beneficial ownership in Crescent Biopharma, acquiring ordinary shares and pre-funded warrants.
Crescent Biopharma, Inc. has granted 142,474 stock options to its Chief Scientific Officer, Jan Pinkas, with an exercise price of $13.14 per share.
GlycoMimetics Inc. Director Susan Moran was granted 9,023 stock options with an exercise price of $15.3 per share, vesting over approximately one year.
Fairmount Funds Management LLC, a 10% owner and director of Glycomimetics Inc., reported the acquisition of 9,023 stock options with an exercise price of $15.30, vesting by June 2026.
GlycoMimetics Inc. Director Jonathan Violin was granted 9,023 stock options with an exercise price of $15.30, vesting based on continued service.
GlycoMimetics Inc. Director Alexandra Balcom was granted 9,023 stock options with an exercise price of $15.30, vesting on the earlier of June 23, 2026, or the next annual meeting.
GlycoMimetics Inc. Director and 10% Owner David Charles Lubner was granted 9,023 stock options with an exercise price of $15.30, aligning his interests with shareholders.